Your shopping cart is currently empty

SRX3212 is a Novel BRD4/PI3Kα inhibitor, displaying an IC50 of 3.7 nM toward BRD4BD1 and 32 nM toward BRD4BD2, and therefore was~65-fold more potent inhibitor of BRD4BD1 and~48-fold more potent inhibitor of BRD4BD2 than SF2523 (GLXC-10641), retaining its high inhibitory activity for PI3Kα (IC50: 22 nM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $1,670 | 6-8 weeks | 6-8 weeks | |
| 50 mg | $2,180 | 6-8 weeks | 6-8 weeks | |
| 100 mg | $2,800 | 6-8 weeks | 6-8 weeks |
| Description | SRX3212 is a Novel BRD4/PI3Kα inhibitor, displaying an IC50 of 3.7 nM toward BRD4BD1 and 32 nM toward BRD4BD2, and therefore was~65-fold more potent inhibitor of BRD4BD1 and~48-fold more potent inhibitor of BRD4BD2 than SF2523 (GLXC-10641), retaining its high inhibitory activity for PI3Kα (IC50: 22 nM). |
| Molecular Weight | 505.54 |
| Formula | C26H23N3O6S |
| Cas No. | 2735720-80-4 |
| Smiles | O=C1C2=C(C(=CS2)C3=CC(C(NCC=4C=CC=NC4)=O)=C5C(=C3)OCCO5)OC(=C1)N6CCOCC6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.